-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insiders Are Probably Glad They Sold Their Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) After 7.4% Drop
Insiders Are Probably Glad They Sold Their Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) After 7.4% Drop
Insiders seem to have made the most of their holdings by selling US$71k worth of Lyell Immunopharma, Inc. (NASDAQ:LYEL) stock at an average sell price of US$6.40 during the past year. After the stock price dropped 7.4% last week, the company's market value declined by US$60m, but insiders were able to mitigate their losses.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Lyell Immunopharma
The Last 12 Months Of Insider Transactions At Lyell Immunopharma
The Founder & Executive Chairman, Richard Klausner, made the biggest insider sale in the last 12 months. That single transaction was for US$71k worth of shares at a price of US$6.40 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$2.99. So it may not shed much light on insider confidence at current levels. The only individual insider seller over the last year was Richard Klausner.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
I will like Lyell Immunopharma better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Insider Ownership Of Lyell Immunopharma
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Lyell Immunopharma insiders own about US$27m worth of shares. That equates to 3.6% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Lyell Immunopharma Tell Us?
The fact that there have been no Lyell Immunopharma insider transactions recently certainly doesn't bother us. Still, the insider transactions at Lyell Immunopharma in the last 12 months are not very heartening. But we do like the fact that insiders own a fair chunk of the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 3 warning signs we've spotted with Lyell Immunopharma (including 1 which makes us a bit uncomfortable).
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
内部人士似乎充分利用了他们所持的股票,出售了价值7.1万美元的莱尔免疫公司。纳斯达克(Sequoia Capital:LYEL)过去一年的平均售价为6.4美元。上周股价下跌7.4%后,该公司市值缩水6000万美元,但内部人士能够减轻他们的损失。
尽管我们不认为股东应该简单地跟踪内幕交易,但我们确实认为,密切关注内部人士的所作所为是完全合乎逻辑的。
查看我们对莱尔免疫咽瘤的最新分析
莱尔免疫公司过去12个月的内幕交易
创始人兼执行主席理查德·克劳斯纳在过去12个月中进行了最大规模的内幕交易。这一笔交易是以每股6.40美元的价格购买了价值7.1万美元的股票。虽然我们通常不喜欢看到内幕出售,但如果以更低的价格出售,人们更担心的是。好消息是,这笔大笔交易的价格远远高于目前2.99美元的价格。因此,在目前的水平上,这可能不会让人对内部人士的信心有太多了解。去年唯一的个人内幕卖家是理查德·克劳斯纳。
你可以看到过去一年的内幕交易(由公司和个人),如下图所示。如果你想知道到底是谁卖了,卖了多少钱,什么时候卖的,只需点击下面的图表!
如果我看到一些内部人士大举买入,我会更喜欢莱尔免疫抗菌素。在我们等待的时候,看看这个免费最近有大量内幕收购的成长型公司名单。
莱尔免疫咽喉病的内部人所有权
许多投资者喜欢查看一家公司有多少股份是由内部人士持有的。我认为,如果内部人士持有该公司大量股份,这是一个好兆头。莱尔免疫内部人士拥有价值约2700万美元的股票。这相当于该公司3.6%的股份。我们当然在其他地方看到了更高水平的内部人持股,但这些持股足以表明内部人和其他股东之间的关系。
莱尔免疫公司的内幕交易可能告诉我们什么?
最近没有莱尔免疫内幕交易这一事实当然不会让我们感到困扰。尽管如此,莱尔免疫公司过去12个月的内幕交易并不太令人振奋。但我们确实喜欢这样一个事实,即内部人士拥有公司的相当大一部分股份。虽然我们喜欢知道内部人士的所有权和交易情况,但在做出任何投资决定之前,我们也要确保考虑到一只股票面临的风险。为此,您应该了解3个警示标志我们已经发现了莱尔免疫瘤(包括1,这让我们有点不舒服)。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费列出了一些有趣的公司,这些公司拥有高股本回报率和低债务。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧